IL6 and Shock: In addition, more than 20 clinical studies are currently registered on ClinicalTrials.gov (accessed on 12 January 2020) that aim to evaluate the efficacy of monoclonal antibodies against IL-6 (e.g., siltuximab, sirukumab, olokizumab, clazakizumab) in Covid-19-induced sepsis and septic shock [93].